Clinical Proteomics of the Neglected Human Malarial Parasite Plasmodium Vivax

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Oct 27

PMID 22028927

Citations 23

Authors

Pragyan Acharya

Rani Pallavi

Syama Chandran

Vrushali Dandavate

Syed Khund Sayeed

Ankit Rochani

Jyoti Acharya

Sheetal Middha

Sanjay Kochar

Dhanpat Kochar

Susanta Kumar Ghosh

Utpal Tatu

Affiliations

Soon will be listed here.

Abstract

Recent reports highlight the severity and the morbidity of disease caused by the long neglected malaria parasite Plasmodium vivax. Due to inherent difficulties in the laboratory-propagation of P. vivax, the biology of this parasite has not been adequately explored. While the proteome of P. falciparum, the causative agent of cerebral malaria, has been extensively explored from several sources, there is limited information on the proteome of P. vivax. We have, for the first time, examined the proteome of P. vivax isolated directly from patients without adaptation to laboratory conditions. We have identified 153 proteins from clinical P. vivax, majority of which do not show homology to any previously known gene products. We also report 29 new proteins that were found to be expressed in P. vivax for the first time. In addition, several proteins previously implicated as anti-malarial targets, were also found in our analysis. Most importantly, we found several unique proteins expressed by P. vivax.This study is an important step in providing insight into physiology of the parasite under clinical settings.

Citing Articles

Decrypting the complexity of the human malaria parasite biology through systems biology approaches.

Chahine Z, Le Roch K Front Syst Biol. 2023; 2.

PMID: 37200864 PMC: 10191146. DOI: 10.3389/fsysb.2022.940321.

Polyclonal Antibody Generation against PvTRAg for the Development of a Diagnostic Assay for .

Aggarwal S, Selvaraj S, Subramanian J, Vijayalakshmi M, Patankar S, Srivastava S Diagnostics (Basel). 2023; 13(5).

PMID: 36899977 PMC: 10001162. DOI: 10.3390/diagnostics13050835.

Plasmodium vivax: the potential obstacles it presents to malaria elimination and eradication.

Habtamu K, Petros B, Yan G Trop Dis Travel Med Vaccines. 2022; 8(1):27.

PMID: 36522671 PMC: 9753897. DOI: 10.1186/s40794-022-00185-3.

The Black Box of Cellular and Molecular Events of Merozoite Invasion into Reticulocytes.

Molina-Franky J, Reyes C, Jaimes Y, Kalkum M, Patarroyo M Int J Mol Sci. 2022; 23(23).

PMID: 36498854 PMC: 9739029. DOI: 10.3390/ijms232314528.

Systems biology of malaria explored with nonhuman primates.

Galinski M Malar J. 2022; 21(1):177.

PMID: 35672852 PMC: 9172618. DOI: 10.1186/s12936-022-04199-2.

References

Dharia N, Bright A, Westenberger S, Barnes S, Batalov S, Kuhen K . Whole-genome sequencing and microarray analysis of ex vivo Plasmodium vivax reveal selective pressure on putative drug resistance genes. Proc Natl Acad Sci U S A. 2010; 107(46):20045-50. PMC: 2993397. DOI: 10.1073/pnas.1003776107. View

Florens L, Washburn M, Raine J, Anthony R, Grainger M, Haynes J . A proteomic view of the Plasmodium falciparum life cycle. Nature. 2002; 419(6906):520-6. DOI: 10.1038/nature01107. View

Korsinczky M, Fischer K, Chen N, Baker J, Rieckmann K, Cheng Q . Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxine-binding site. Antimicrob Agents Chemother. 2004; 48(6):2214-22. PMC: 415609. DOI: 10.1128/AAC.48.6.2214-2222.2004. View

Collins W, Jeffery G . Primaquine resistance in Plasmodium vivax. Am J Trop Med Hyg. 1996; 55(3):243-9. DOI: 10.4269/ajtmh.1996.55.243. View

Joubert F, Neitz A, Louw A . Structure-based inhibitor screening: a family of sulfonated dye inhibitors for malaria parasite triosephosphate isomerase. Proteins. 2001; 45(2):136-43. DOI: 10.1002/prot.1133. View

Fraser T, Michon P, Barnwell J, Noe A, Kaslow D, Adams J . Expression and serologic activity of a soluble recombinant Plasmodium vivax Duffy binding protein. Infect Immun. 1997; 65(7):2772-7. PMC: 175391. DOI: 10.1128/iai.65.7.2772-2777.1997. View

Baird J, Schwartz E, Hoffman S . Prevention and treatment of vivax malaria. Curr Infect Dis Rep. 2007; 9(1):39-46. DOI: 10.1007/s11908-007-0021-4. View

Date S, Stoeckert Jr C . Computational modeling of the Plasmodium falciparum interactome reveals protein function on a genome-wide scale. Genome Res. 2006; 16(4):542-9. PMC: 1457034. DOI: 10.1101/gr.4573206. View

Goh S, Josleyn M, Lee Y, Danner R, Gherman R, Cam M . The human reticulocyte transcriptome. Physiol Genomics. 2007; 30(2):172-8. DOI: 10.1152/physiolgenomics.00247.2006. View

10.

Trenholme K, Brown C, Skinner-Adams T, Stack C, Lowther J, To J . Aminopeptidases of malaria parasites: new targets for chemotherapy. Infect Disord Drug Targets. 2010; 10(3):217-25. DOI: 10.2174/187152610791163363. View

11.

Pesce E, Cockburn I, Goble J, Stephens L, Blatch G . Malaria heat shock proteins: drug targets that chaperone other drug targets. Infect Disord Drug Targets. 2010; 10(3):147-57. DOI: 10.2174/187152610791163417. View

12.

Granchi C, Bertini S, Macchia M, Minutolo F . Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Curr Med Chem. 2010; 17(7):672-97. DOI: 10.2174/092986710790416263. View

13.

LeRoux M, Lakshmanan V, Daily J . Plasmodium falciparum biology: analysis of in vitro versus in vivo growth conditions. Trends Parasitol. 2009; 25(10):474-81. DOI: 10.1016/j.pt.2009.07.005. View

14.

Fernandez-Becerra C, Yamamoto M, Vencio R, Lacerda M, Rosanas-Urgell A, Del Portillo H . Plasmodium vivax and the importance of the subtelomeric multigene vir superfamily. Trends Parasitol. 2008; 25(1):44-51. DOI: 10.1016/j.pt.2008.09.012. View

15.

Mendis K, Sina B, Marchesini P, Carter R . The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001; 64(1-2 Suppl):97-106. DOI: 10.4269/ajtmh.2001.64.97. View

16.

Carlton J, Adams J, Silva J, Bidwell S, Lorenzi H, Caler E . Comparative genomics of the neglected human malaria parasite Plasmodium vivax. Nature. 2008; 455(7214):757-63. PMC: 2651158. DOI: 10.1038/nature07327. View

17.

Wanidworanun C, Nagel R, Shear H . Antisense oligonucleotides targeting malarial aldolase inhibit the asexual erythrocytic stages of Plasmodium falciparum. Mol Biochem Parasitol. 1999; 102(1):91-101. DOI: 10.1016/s0166-6851(99)00087-0. View

18.

McGowan S, Porter C, Lowther J, Stack C, Golding S, Skinner-Adams T . Structural basis for the inhibition of the essential Plasmodium falciparum M1 neutral aminopeptidase. Proc Natl Acad Sci U S A. 2009; 106(8):2537-42. PMC: 2636733. DOI: 10.1073/pnas.0807398106. View

19.

Pallavi R, Roy N, Nageshan R, Talukdar P, Pavithra S, Reddy R . Heat shock protein 90 as a drug target against protozoan infections: biochemical characterization of HSP90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug. J Biol Chem. 2010; 285(49):37964-75. PMC: 2992230. DOI: 10.1074/jbc.M110.155317. View

20.

Jalah R, Sarin R, Sud N, Alam M, Parikh N, Das T . Identification, expression, localization and serological characterization of a tryptophan-rich antigen from the human malaria parasite Plasmodium vivax. Mol Biochem Parasitol. 2005; 142(2):158-69. DOI: 10.1016/j.molbiopara.2005.01.020. View